Matches in SemOpenAlex for { <https://semopenalex.org/work/W3141584887> ?p ?o ?g. }
Showing items 1 to 92 of
92
with 100 items per page.
- W3141584887 endingPage "5789" @default.
- W3141584887 startingPage "5779" @default.
- W3141584887 abstract "Advances in molecular research in cancer have brought new therapeutic strategies into clinical usage.One new group of targets is tyrosine kinase receptors,which can be treated by several strategies,including small molecule tyrosine kinase inhibitors(TKIs) and monoclonal antibodies(mAbs).Aberrant activation of growth factors/receptors and their signal pathways are required for malignant transformation and progression in gastrointestinal(GI) carcinomas.The concept of targeting specif ic carcinogenic receptors has been validated by successful clinical application of many new drugs.Type I insulin-like growth factor(IGF) receptor(IGF-IR) signaling potently stimulates tumor progression and cellular differentiation,and is a promising new molecular target in human malignancies.In this review,we focus on this promising therapeutic target,IGF-IR.The IGF/IGF-IR axis is an important modifier of tumor cell proliferation,survival,growth,and treatment sensitivity in many malignant diseases,including human GI cancers.Preclinical studies demonstrated that downregulation of IGF-IR signals reversed the neoplastic phenotype and sensitized cells to anticancer treatments.These results were mainly obtained through our strategy of adenoviruses expressing dominant negative IGF-IR(IGF-IR/dn) against gastrointestinal cancers,including esophagus,stomach,colon,and pancreas.We also summarize a variety of strategies to interrupt the IGFs/IGF-IR axis and their preclinical experiences.Several mAbs and TKIs targeting IGF-IR have entered clinical trials,and early results have suggested that these agents have generally acceptable safety profiles as single agents.We summarize the advantages and disadvantages of each strategy and discuss the merits/demerits of dual targeting of IGF-IR and other growth factor receptors,including Her2 and the insulin receptor,as well as other alternatives and possible drug combinations.Thus,IGF-IR might be a candidate for a molecular therapeutic target in human GI carcinomas." @default.
- W3141584887 created "2021-04-13" @default.
- W3141584887 creator A5007147758 @default.
- W3141584887 creator A5015398167 @default.
- W3141584887 creator A5016890340 @default.
- W3141584887 creator A5021185806 @default.
- W3141584887 creator A5027673587 @default.
- W3141584887 creator A5027723130 @default.
- W3141584887 creator A5036465589 @default.
- W3141584887 creator A5036635923 @default.
- W3141584887 creator A5045745778 @default.
- W3141584887 creator A5046102207 @default.
- W3141584887 creator A5057559744 @default.
- W3141584887 creator A5069647051 @default.
- W3141584887 creator A5071207044 @default.
- W3141584887 creator A5090885773 @default.
- W3141584887 date "2010-01-01" @default.
- W3141584887 modified "2023-09-24" @default.
- W3141584887 title "A candidate targeting molecule of insulin-like growth factor-I receptor for gastrointestinal cancers" @default.
- W3141584887 hasPublicationYear "2010" @default.
- W3141584887 type Work @default.
- W3141584887 sameAs 3141584887 @default.
- W3141584887 citedByCount "0" @default.
- W3141584887 crossrefType "journal-article" @default.
- W3141584887 hasAuthorship W3141584887A5007147758 @default.
- W3141584887 hasAuthorship W3141584887A5015398167 @default.
- W3141584887 hasAuthorship W3141584887A5016890340 @default.
- W3141584887 hasAuthorship W3141584887A5021185806 @default.
- W3141584887 hasAuthorship W3141584887A5027673587 @default.
- W3141584887 hasAuthorship W3141584887A5027723130 @default.
- W3141584887 hasAuthorship W3141584887A5036465589 @default.
- W3141584887 hasAuthorship W3141584887A5036635923 @default.
- W3141584887 hasAuthorship W3141584887A5045745778 @default.
- W3141584887 hasAuthorship W3141584887A5046102207 @default.
- W3141584887 hasAuthorship W3141584887A5057559744 @default.
- W3141584887 hasAuthorship W3141584887A5069647051 @default.
- W3141584887 hasAuthorship W3141584887A5071207044 @default.
- W3141584887 hasAuthorship W3141584887A5090885773 @default.
- W3141584887 hasConcept C101544691 @default.
- W3141584887 hasConcept C121608353 @default.
- W3141584887 hasConcept C126322002 @default.
- W3141584887 hasConcept C170493617 @default.
- W3141584887 hasConcept C26375932 @default.
- W3141584887 hasConcept C2775960820 @default.
- W3141584887 hasConcept C2780689927 @default.
- W3141584887 hasConcept C2908605954 @default.
- W3141584887 hasConcept C42362537 @default.
- W3141584887 hasConcept C502942594 @default.
- W3141584887 hasConcept C71924100 @default.
- W3141584887 hasConcept C86803240 @default.
- W3141584887 hasConceptScore W3141584887C101544691 @default.
- W3141584887 hasConceptScore W3141584887C121608353 @default.
- W3141584887 hasConceptScore W3141584887C126322002 @default.
- W3141584887 hasConceptScore W3141584887C170493617 @default.
- W3141584887 hasConceptScore W3141584887C26375932 @default.
- W3141584887 hasConceptScore W3141584887C2775960820 @default.
- W3141584887 hasConceptScore W3141584887C2780689927 @default.
- W3141584887 hasConceptScore W3141584887C2908605954 @default.
- W3141584887 hasConceptScore W3141584887C42362537 @default.
- W3141584887 hasConceptScore W3141584887C502942594 @default.
- W3141584887 hasConceptScore W3141584887C71924100 @default.
- W3141584887 hasConceptScore W3141584887C86803240 @default.
- W3141584887 hasIssue "46" @default.
- W3141584887 hasLocation W31415848871 @default.
- W3141584887 hasOpenAccess W3141584887 @default.
- W3141584887 hasPrimaryLocation W31415848871 @default.
- W3141584887 hasRelatedWork W1589360059 @default.
- W3141584887 hasRelatedWork W1978308081 @default.
- W3141584887 hasRelatedWork W2042741680 @default.
- W3141584887 hasRelatedWork W2049388837 @default.
- W3141584887 hasRelatedWork W2067337319 @default.
- W3141584887 hasRelatedWork W2084545997 @default.
- W3141584887 hasRelatedWork W2093221289 @default.
- W3141584887 hasRelatedWork W2097888739 @default.
- W3141584887 hasRelatedWork W2099804286 @default.
- W3141584887 hasRelatedWork W2119418459 @default.
- W3141584887 hasRelatedWork W2120070286 @default.
- W3141584887 hasRelatedWork W2144230749 @default.
- W3141584887 hasRelatedWork W2154518689 @default.
- W3141584887 hasRelatedWork W2168272067 @default.
- W3141584887 hasRelatedWork W2411113986 @default.
- W3141584887 hasRelatedWork W2417725913 @default.
- W3141584887 hasRelatedWork W2789824316 @default.
- W3141584887 hasRelatedWork W3086639494 @default.
- W3141584887 hasRelatedWork W32517517 @default.
- W3141584887 hasRelatedWork W40744503 @default.
- W3141584887 isParatext "false" @default.
- W3141584887 isRetracted "false" @default.
- W3141584887 magId "3141584887" @default.
- W3141584887 workType "article" @default.